| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Mohammad Hadi Aarabi | Q50016723 |
| P2093 | author name string | Soheil Mohammadi | |
| Fatemeh Moosaie | |||
| P2860 | cites work | Pathogenesis of murine coronavirus in the central nervous system | Q34039962 |
| Anosmia is very common in the Lewy body variant of Alzheimer's disease | Q35484548 | ||
| Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV) | Q35905508 | ||
| Experimental optic neuritis induced by a demyelinating strain of mouse hepatitis virus. | Q36845899 | ||
| Age, APOE and sex: Triad of risk of Alzheimer's disease | Q36998533 | ||
| Angiotensin-converting enzyme 2 in the brain: properties and future directions | Q37155907 | ||
| Inflammatory cytokines in experimental and human stroke. | Q38022155 | ||
| Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau. | Q38686402 | ||
| The role of interleukin-6 signaling in nervous tissue | Q38789542 | ||
| Neuroinflammation in Alzheimer's disease: Current evidence and future directions | Q38834651 | ||
| Parkinson's disease: Autoimmunity and neuroinflammation. | Q38920713 | ||
| Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. | Q38983429 | ||
| Advances in markers of prodromal Parkinson disease | Q38992302 | ||
| Non-motor features of Parkinson disease | Q39358549 | ||
| Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection. | Q40395618 | ||
| Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). | Q40473391 | ||
| Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation | Q40948608 | ||
| Different mechanisms of inflammation induced in virus and autoimmune-mediated models of multiple sclerosis in C57BL6 mice. | Q42030864 | ||
| Gut microbiome alterations in Alzheimer's disease | Q42670350 | ||
| Exploring white matter microstructure and olfaction dysfunction in early parkinson disease: diffusion MRI reveals new insight | Q47218321 | ||
| Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/C mice | Q48623426 | ||
| Association Between Peripheral Inflammation and DATSCAN Data of the Striatal Nuclei in Different Motor Subtypes of Parkinson Disease. | Q55228224 | ||
| Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease | Q64864668 | ||
| Olfactory Dysfunction in Coronavirus Disease 2019 Patients: Observational Cohort Study and Systematic Review | Q96435580 | ||
| Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study | Q96437052 | ||
| Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of current evidence | Q96581609 | ||
| Changing dynamics of psychoneuroimmunology during the COVID-19 pandemic | Q96609450 | ||
| Neurological involvement of coronavirus disease 2019: a systematic review | Q96610556 | ||
| Psycho-Neuroendocrine-Immune Interactions in COVID-19: Potential Impacts on Mental Health | Q96647322 | ||
| Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis | Q96687425 | ||
| Is a "Cytokine Storm" Relevant to COVID-19? | Q96825048 | ||
| Intact Brain Network Function in an Unresponsive Patient with COVID-19 | Q96958648 | ||
| Neurological associations of COVID-19 | Q97075306 | ||
| Coronavirus Disease 2019 and Stroke | Q97414301 | ||
| Postinfectious brainstem encephalitis associated with SARS-CoV-2 | Q97417082 | ||
| The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings | Q97426603 | ||
| Multiple sclerosis following SARS-CoV-2 infection | Q97650699 | ||
| Immune-mediated neurological syndromes in SARS-CoV-2-infected patients | Q98179090 | ||
| Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection | Q98514061 | ||
| Cerebrovascular disease in COVID-19: Is there a higher risk of stroke? | Q98657558 | ||
| SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor | Q88292103 | ||
| Nervous system involvement after infection with COVID-19 and other coronaviruses | Q91512172 | ||
| A Systematic Review of COVID-19 Epidemiology Based on Current Evidence | Q91541035 | ||
| Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China | Q91802849 | ||
| Autoimmunity and cytokines in Guillain-Barré syndrome revisited: review of pathomechanisms with an eye on therapeutic options | Q91910854 | ||
| Neurologic Features in Severe SARS-CoV-2 Infection | Q91957408 | ||
| Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms | Q91990275 | ||
| Guillain-Barré Syndrome Associated with SARS-CoV-2 | Q92014375 | ||
| Miller Fisher Syndrome and polyneuritis cranialis in COVID-19 | Q92024975 | ||
| Antibody Detection and Dynamic Characteristics in Patients with COVID-19 | Q92041532 | ||
| Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments | Q92191065 | ||
| Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model | Q92529012 | ||
| Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease | Q93083686 | ||
| The Properties of Cytokines in Multiple Sclerosis: Pros and Cons | Q93190203 | ||
| Is the Collapse of the Respiratory Center in the Brain Responsible for Respiratory Breakdown in COVID-19 Patients? | Q94457125 | ||
| COVID-19 presenting with ophthalmoparesis from cranial nerve palsy | Q94482815 | ||
| SARS-CoV-2 can induce brain and spine demyelinating lesions | Q94522568 | ||
| Brain MRI Findings in Patients in the Intensive Care Unit with COVID-19 Infection | Q94562977 | ||
| 18FDG PET/CT Scan Reveals Hypoactive Orbitofrontal Cortex in Anosmia of COVID-19 | Q94587470 | ||
| SARS-CoV-2: "Three-steps" infection model and CSF diagnostic implication | Q94589255 | ||
| Expression of the SARS-CoV-2 Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of Cell Types and Trends with Age | Q94604936 | ||
| Cerebrovascular Disease in COVID-19 | Q94684315 | ||
| Seizures associated with coronavirus infections | Q94951829 | ||
| Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review | Q95298763 | ||
| Evolution and resolution of brain involvement associated with SARS- CoV2 infection: A close Clinical – Paraclinical follow up study of a case | Q95604521 | ||
| Corona Viruses and the Chemical Senses: Past, Present, and Future | Q95628666 | ||
| COVID-19 related neuroimaging findings: A signal of thromboembolic complications and a strong prognostic marker of poor patient outcome | Q95639569 | ||
| APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort | Q95832966 | ||
| Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms | Q95843449 | ||
| COVID-19-Associated Miller Fisher Syndrome: MRI Findings | Q95935244 | ||
| Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review | Q95941739 | ||
| Cerebrovascular and Neurological Dysfunction under the Threat of COVID-19: Is There a Comorbid Role for Smoking and Vaping? | Q96116486 | ||
| Cranial Neuropathies and COVID-19: Neurotropism and Autoimmunity | Q96125326 | ||
| Immediate and long-term consequences of COVID-19 infections for the development of neurological disease | Q96130910 | ||
| Neurological complications of COVID-19: a preliminary review | Q96138210 | ||
| A review of pathophysiology and neuropsychiatric manifestations of COVID-19 | Q96138217 | ||
| Multifocal laminar cortical brain lesions: a consistent MRI finding in neuro-COVID-19 patients | Q96162514 | ||
| Guillain-Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing | Q96229357 | ||
| Potential Novel Role of COVID-19 in Alzheimer's Disease and Preventative Mitigation Strategies | Q96351281 | ||
| Neurobiology of COVID-19 | Q96351286 | ||
| Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19 | Q96431591 | ||
| P921 | main subject | neurological disorder | Q3339235 |
| SARS-CoV-2 | Q82069695 | ||
| P577 | publication date | 2020-09-01 | |
| 2020-12-01 | |||
| P1433 | published in | Molecular Neurobiology | Q15716645 |
| P1476 | title | Understanding the Immunologic Characteristics of Neurologic Manifestations of SARS-CoV-2 and Potential Immunological Mechanisms |
| Q104506768 | Meta-analysis of EEG findings in patients with COVID-19 | cites work | P2860 |
Search more.